SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC trades jubilantly on receiving USFDA approval for ‘ELEPSIA XR’ extended-release tablets

09 Mar 2015 Evaluate

Sun Pharma Advanced Research Company (SPARC) is currently trading at Rs. 547.25, up by 73.70 points or 15.56% from its previous closing of Rs. 473.55 on the BSE.

The scrip opened at Rs. 477.00 and has touched a high and low of Rs. 565.00 and Rs. 475.00 respectively. So far 1795333 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 565.00 on 09-Mar-2015 and a 52 week low of Rs. 144.10 on 31-Mar-2014.

Last one week high and low of the scrip stood at Rs. 565.00 and Rs. 370.90 respectively. The current market cap of the company is Rs. 12896.84 crore.

The promoters holding in the company stood at 67.13% while Institutions and Non-Institutions held 6.00% and 26.87% respectively.

SPARC has received an approval from US Food and Drug Administration (USFDA) for its New Drug Application (NDA) for ELEPSIA XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg).

ELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. The product will be manufactured by Sun Pharmaceutical Industries at its Halol facility in Gujarat.

Sun Pharma Advanced Research Company (SPARC) is an international pharmaceutical company engaged in research and development of drugs and delivery systems. 

 

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×